Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Estornut (Valencia, Spain), P. Ribera (Valencia, Spain), A. Bayarri (Valencia, Spain), P. Montero (Valencia, Spain), J. Cortijo (Valencia, Spain). Omaveloxolone, CDDO-Me and Obacunone as promising therapeutic options in COPD. 180

Member's Comments

No comment yet.

Related content which might interest you: How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 GED-0507 as a novel anti-fibrotic treatment option for pulmonary fibrosis Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018 Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Pharmacological options for the treatment of COPD: present and future Source: Annual Congress 2007 - PG6 - COPD: comprehensive clinical assessment and pharmacological and nonpharmacological therapy Year: 2007 Treatment of COPD: from pharmacological to instrumental therapies Source: Eur Respir Rev 2009; 19: 7-23 Year: 2010 GRC39815-A novel inhaled ROR?t inhibitor as a potential first in class treatment option for COPD Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies Year: 2021 Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment Source: Eur Respir Rev, 30 (162) 210093; 10.1183/16000617.0093-2021 Year: 2021 The promise of mTOR signaling as a therapeutic target for IPF Source: Virtual Congress 2020 – Reflections from the Lung Science 2020 conference Year: 2020 Lots of promising targets and biomarkers, but how can we deliver the next generation of severe asthma trials? Source: International Congress 2019 – Beyond T2 mechanisms in asthma: who are the other players? Year: 2019 Novel targets and emerging therapies in MPM Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systems Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 29 (157) 200269; 10.1183/16000617.0269-2020 Year: 2020 Is hyaluronic acid (HA) a marker of effectiveness of anti-inflammatory therapy in COPD patients? Source: Annual Congress 2013 –COPD: markers and inflammation Year: 2013 In vitro pharmacological profile of SMP-028, a novel potent anti-inflammatory agent Source: Annual Congress 2010 - Models of airways disease Year: 2010 Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations Source: Eur Respir J, 50 (4) 1602434; 10.1183/13993003.02434-2016 Year: 2017